| Year |
Citation |
Score |
| 2020 |
Peterson LM, Kurland BF, Yan F, Novakova-Jiresova A, Gadi VK, Specht JM, Gralow JR, Schubert EK, Link JM, Krohn KA, Eary JF, Mankoff DA, Linden HM. F-Fluoroestradiol (F-FES)-PET imaging in a Phase II trial of vorinostat to restore endocrine sensitivity in ER+/HER2- metastatic breast cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 32591490 DOI: 10.2967/Jnumed.120.244459 |
0.376 |
|
| 2020 |
Kurland BF, Wiggins JR, Coche A, Fontan C, Bouvet Y, Webner P, Divgi C, Linden HM. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications. The Oncologist. PMID 32374053 DOI: 10.1634/Theoncologist.2019-0967 |
0.392 |
|
| 2020 |
Manohar P, Peterson L, Wu Q(, Jenkins I, Kurland B, Novakova-Jiresova A, Specht J, Muzi M, Link J, Krohn K, Kinahan P, Mankoff D, Linden H. Abstract P1-01-07: The role of 18F-Fluoroestradiol (FES) and 18F-Fluorodeoxyglucose (FDG) PET imaging in identification of bone metastases in metastatic breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P1-01-07 |
0.366 |
|
| 2019 |
Mrugala MM, Kim B, Sharma A, Johnson N, Graham C, Kurland BF, Gralow J. Phase II Study of Systemic High-dose Methotrexate and Intrathecal Liposomal Cytarabine for Treatment of Leptomeningeal Carcinomatosis From Breast Cancer. Clinical Breast Cancer. PMID 31175053 DOI: 10.1016/J.Clbc.2019.04.004 |
0.359 |
|
| 2018 |
Symonds L, Linden H, Gadi V, Korde L, Rodler E, Gralow J, Redman M, Baker K, Wu QV, Jenkins I, Kurland B, Garrison M, Smith J, Anderson J, Van Haelst C, et al. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib. Clinical Breast Cancer. PMID 30737173 DOI: 10.1016/J.Clbc.2018.12.008 |
0.346 |
|
| 2018 |
Kurland BF, Peterson LM, Shields AT, Lee JH, Byrd DW, Novakova-Jiresova A, Muzi M, Specht JM, Mankoff DA, Linden HM, Kinahan PE. Test-retest reproducibility of FDG-PET/CT uptake in cancer patients within a qualified and calibrated local network. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 30361381 DOI: 10.2967/Jnumed.118.209544 |
0.367 |
|
| 2018 |
Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA, Linden HM. Correction to: a Phase 2 Study of 16α-[18F]-Fluoro-17β-Estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC). Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 30324461 DOI: 10.1007/S11307-018-1287-7 |
0.34 |
|
| 2018 |
Kurland BF, Oesterreich S. Heterogeneity in metastatic breast cancer F-fluoroestradiol uptake - clinically actionable, biologically illuminating? Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29903931 DOI: 10.2967/Jnumed.118.214304 |
0.359 |
|
| 2017 |
Chang AE, Wu QV, Jenkins IC, Specht JM, Gadi VK, Gralow JR, Salazar LG, Kurland BF, Linden HM. Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer. Clinical Breast Cancer. PMID 29174203 DOI: 10.1016/J.Clbc.2017.10.005 |
0.355 |
|
| 2017 |
Wu S, Zuley ML, Berg WA, Kurland BF, Jankowitz RC, Sumkin JH, Gur D. DCE-MRI Background Parenchymal Enhancement Quantified from an Early versus Delayed Post-contrast Sequence: Association with Breast Cancer Presence. Scientific Reports. 7: 2115. PMID 28522877 DOI: 10.1038/S41598-017-02341-8 |
0.364 |
|
| 2017 |
Bhattacharya S, Somasundaram A, Ding F, Gaither-Davis A, Pennathur A, LaFramboise WA, Dacic S, Kurland BF, Stabile LP, Burns TF. Alterations in the Β-catenin pathway in non-small cell lung cancer to define a distinct molecular subtype with prognostic and therapeutic implications. Journal of Clinical Oncology. 35: 11584-11584. DOI: 10.1200/Jco.2017.35.15_Suppl.11584 |
0.304 |
|
| 2017 |
Peterson LM, Kurland BF, Novakova A, Lee JH, Specht JM, Muzi M, Romine P, Wu V, Mankoff DA, Kinahan P, Linden HM. The use of 18F-fluoroestradiol (FES) and 18F-fluorodeoxyglucose (FDG) PET in the evaluation of breast cancer heterogeneity. Journal of Clinical Oncology. 35: 11572-11572. DOI: 10.1200/Jco.2017.35.15_Suppl.11572 |
0.42 |
|
| 2017 |
Specht J, Gadi V, Gralow J, Korde L, Linden H, Salazar L, Rodler E, Cundy A, Buening B, Baker K, Redman M, Kurland B, Garrison M, Smith J, vanHaelst C, et al. Abstract P4-22-11: Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P4-22-11 |
0.38 |
|
| 2017 |
Linden H, Peterson L, Kurland B, Roberts T, Specht J, Shields A, Novakova A, Christopfel R, Byrd D, Muzi M, Mankoff D, Kinahan P. Abstract P4-02-05: Test-retest fidelity of FDG SUVmax in bone and non-boney metastatic breast cancer lesions in local area network PET/CT scanners Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P4-02-05 |
0.389 |
|
| 2016 |
Wu S, Berg WA, Zuley ML, Kurland BF, Jankowitz RC, Nishikawa R, Gur D, Sumkin JH. Breast MRI contrast enhancement kinetics of normal parenchyma correlate with presence of breast cancer. Breast Cancer Research : Bcr. 18: 76. PMID 27449059 DOI: 10.1186/S13058-016-0734-0 |
0.345 |
|
| 2016 |
Kurland BF, Peterson LM, Lee JH, Schubert EK, Currin ER, Link JM, Krohn KA, Mankoff DA, Linden HM. Estrogen receptor binding (FES PET) and glycolytic activity (FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27342400 DOI: 10.1158/1078-0432.Ccr-16-0362 |
0.401 |
|
| 2016 |
Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Stychor S, Kiesel B, Linden HM, Thompson JA, Swisher EM, et al. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26801247 DOI: 10.1158/1078-0432.Ccr-15-2137 |
0.349 |
|
| 2016 |
Kurland BF, Muzi M, Peterson LM, Doot RK, Wangerin KA, Mankoff DA, Linden HM, Kinahan PE. Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 57: 226-30. PMID 26493206 DOI: 10.2967/Jnumed.115.162289 |
0.344 |
|
| 2016 |
Roberts TK, Peterson L, Kurland B, Novakova A, Shields A, Doot RK, Schubert EK, Gadi VK, Specht JM, Gralow J, Eary JF, Muzi M, Link J, Krohn KA, Mankoff DA, et al. Use of serial 18F-Fluorothymidine (FLT) PET and Ki-67 to predict response to aromatase inhibitors (AI) in women with ER+ breast cancer. Journal of Clinical Oncology. 34: e12039-e12039. DOI: 10.1200/Jco.2016.34.15_Suppl.E12039 |
0.403 |
|
| 2016 |
Jankowitz R, McAuliffe P, Sikora M, Butler L, Ahrendt G, Johnson R, Diego E, Bonaventura M, Puhalla S, Lembersky B, Clark B, Brufsky A, Kurland B, Davidson N, Dabbs D, et al. Abstract P3-05-14: A neoadjuvant window trial of endocrine response in women with invasive lobular carcinoma Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-05-14 |
0.393 |
|
| 2015 |
Wang P, Bahreini A, Gyanchandani R, Lucas P, Hartmaier RJ, Watters RJ, Jonnalagadda AR, Trejo Bittar HE, Berg A, Hamilton RL, Kurland BF, Weiss K, Mathew A, Leone JP, Davidson NE, et al. Sensitive detection of mono- and polyclonal ESR1 mutations in primary tumors, metastatic lesions and cell free DNA of breast cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26500237 DOI: 10.1158/1078-0432.Ccr-15-1534 |
0.343 |
|
| 2015 |
Linden HM, Peterson L, Kurland BF, Novakova A, Shields A, Gadi VK, Specht JM, Muzi M, Kinahan P, Mankoff DA. FLT-PET (Fluorothymidine) and Ki-67 to measure effects of a short course of aromatase inhibitor therapy in ER+ breast cancer patients. Journal of Clinical Oncology. 33: e22161-e22161. DOI: 10.1200/Jco.2015.33.15_Suppl.E22161 |
0.384 |
|
| 2015 |
Puhalla S, Wang P, Bahreini A, Gyanchandani R, Ambros TF, Hartmaier RJ, Kurland BF, Lucas PC, Trejo Bittar HE, Hamilton RL, Mathew A, Leone JP, Davidson NE, Weiss KR, Watters RJ, et al. Detection and functional analysis of estrogen receptor mutations (ESR1-mut) in patients with metastatic breast cancer (MBC). Journal of Clinical Oncology. 33: 554-554. DOI: 10.1200/Jco.2015.33.15_Suppl.554 |
0.358 |
|
| 2015 |
Linden HM, Specht J, Peterson L, Kurland B, Shields A, Byrd D, Novakova A, Christofel R, Muzi M, Mankoff D, Paul K. Abstract P5-01-07: Fidelity of FDG-PET in breast cancer: Reproducibility at multiple sites Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P5-01-07 |
0.393 |
|
| 2015 |
Wu S, Berg WA, Zuley ML, Kurland BF, Jankowitz RC, Sumkin J, Nishikawa RM, Gur D. Abstract P1-01-07: Quantitative assessment of early- and delayed DCE-MRI background parenchymal enhancement in breast cancer risk prediction Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P1-01-07 |
0.363 |
|
| 2015 |
Wu S, Zuley ML, Kurland BF, Jankowitz RC, Sumkin J, Gur D. Abstract P1-01-06: Quantitative breast DCE-MRI risk biomarkers and breast tumor immunohistochemistry phenotypes: A preliminary assessment Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P1-01-06 |
0.388 |
|
| 2015 |
Wu S, Kurland BF, Berg WA, Zuley ML, Jankowitz RC, Sumkin J, Gur D. Signal enhancement ratio (SER) quantified from breast DCE-MRI and breast cancer risk Progress in Biomedical Optics and Imaging - Proceedings of Spie. 9414. DOI: 10.1117/12.2082466 |
0.364 |
|
| 2014 |
Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA, Linden HM. A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC). Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 16: 431-40. PMID 24170452 DOI: 10.1007/S11307-013-0699-7 |
0.333 |
|
| 2014 |
Linden HM, Kurland BF, Link J, Novakova A, Chai X, Specht JM, Gadi VK, Gralow J, Schubert EK, Peterson L, Eary JF, Shields A, Mankoff DA, Krohn KA. A phase II clinical trial of HDACi (vorinostat) and AI therapy in breast cancer with molecular imaging correlates. Journal of Clinical Oncology. 32: 556-556. DOI: 10.1200/Jco.2014.32.15_Suppl.556 |
0.425 |
|
| 2014 |
Rodler ET, Gralow J, Kurland BF, Griffin M, Yeh R, Thompson JA, Porter P, Swisher EM, Gadi VK, Korde LA, Linden HM, Ellis GK, Shepherd SP, Giranda VL, Chai X, et al. Phase I: Veliparib with cisplatin (CP) and vinorelbine (VNR) in advanced triple-negative breast cancer (TNBC) and/or BRCA mutation-associated breast cancer. Journal of Clinical Oncology. 32: 2569-2569. DOI: 10.1200/Jco.2014.32.15_Suppl.2569 |
0.353 |
|
| 2014 |
Stabile LP, Rothstein ME, Kurland BF, Cunningham D, Orlowski M, Siegfried JM. Abstract 608: Targeting the estrogen pathway in a male mouse model of lung tumor prevention Cancer Research. 74: 608-608. DOI: 10.1158/1538-7445.Am2014-608 |
0.322 |
|
| 2013 |
Kurland BF, Doot RK, Linden HM, Mankoff DA, Kinahan PE. Multicenter trials using ¹⁸F-fluorodeoxyglucose (FDG) PET to predict chemotherapy response: effects of differential measurement error and bias on power calculations for unselected and enrichment designs. Clinical Trials (London, England). 10: 886-95. PMID 24169628 DOI: 10.1177/1740774513506618 |
0.328 |
|
| 2013 |
Qu X, Randhawa G, Friedman C, Kurland BF, Glaskova L, Coleman I, Mostaghel E, Higano CS, Porter C, Vessella R, Nelson PS, Fang M. A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors. Plos One. 8: e74671. PMID 24098661 DOI: 10.1371/Journal.Pone.0074671 |
0.308 |
|
| 2013 |
Arora M, Pidala J, Cutler CS, Chai X, Kurland B, Jacobsohn DA, Pavletic SZ, Palmer J, Vogelsang G, Jagasia M, Schultz K, Lee SJ. Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study. Leukemia. 27: 1196-201. PMID 23047477 DOI: 10.1038/Leu.2012.292 |
0.32 |
|
| 2013 |
Specht JM, Kurland BF, Linden HM, Gralow J, Gadi VK, Ellis GK, Rodler ET, Chai X, Eun J, Brown-Glaberman UA, Livingston RB. A phase II study evaluating the safety and efficacy of sunitinib with weekly paclitaxel followed by doxorubicin and daily oral cyclophosphamide plus G-CSF as neoadjuvant chemotherapy (NC) for locally advanced (LABC) or inflammatory breast cancer (IBC). Journal of Clinical Oncology. 31: 1090-1090. DOI: 10.1200/Jco.2013.31.15_Suppl.1090 |
0.326 |
|
| 2013 |
Brown-Glaberman UA, Specht JM, Iannone M, Kurland BF, Livingston RB, Stopeck A. Circulating biomarkers in patients receiving neoadjuvant chemotherapy combined with sunitinib for locally advanced breast cancer. Journal of Clinical Oncology. 31: 1089-1089. DOI: 10.1200/Jco.2013.31.15_Suppl.1089 |
0.377 |
|
| 2013 |
Linden H, Kurland B, Link J, Novakova A, Chai X, Specht J, Gadi V, Gralow J, Schubert E, Peterson L, Eary J, Shields A, Mankoff D, Krohn K. Abstract P4-01-03: HDACi (vorinostat) in metastatic breast cancer to restore sensitivity to ER-directed (AI) therapy: A phase II clinical trial with FES imaging correlates Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-01-03 |
0.428 |
|
| 2013 |
Linden H, Kurland B, Link J, Novakova A, Chai X, Gadi V, Specht J, Hills D, Gralow J, Schubert E, Korde L, Peterson L, Doot R, Eary J, Shields A, et al. Abstract P4-01-02: The role of FLT PET early assessment of response to endocrine therapy for early stage breast cancer Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-01-02 |
0.41 |
|
| 2012 |
Kurland BF, Gerstner ER, Mountz JM, Schwartz LH, Ryan CW, Graham MM, Buatti JM, Fennessy FM, Eikman EA, Kumar V, Forster KM, Wahl RL, Lieberman FS. Promise and pitfalls of quantitative imaging in oncology clinical trials. Magnetic Resonance Imaging. 30: 1301-12. PMID 22898682 DOI: 10.1016/J.Mri.2012.06.009 |
0.353 |
|
| 2012 |
Muzi M, O'Sullivan F, Mankoff DA, Doot RK, Pierce LA, Kurland BF, Linden HM, Kinahan PE. Quantitative assessment of dynamic PET imaging data in cancer imaging. Magnetic Resonance Imaging. 30: 1203-15. PMID 22819579 DOI: 10.1016/J.Mri.2012.05.008 |
0.306 |
|
| 2012 |
Kurland BF, Gadi VK, Specht JM, Allison KH, Livingston RB, Rodler ET, Peterson LM, Schubert EK, Chai X, Mankoff DA, Linden HM. Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. Ejnmmi Research. 2: 34. PMID 22731662 DOI: 10.1186/2191-219X-2-34 |
0.395 |
|
| 2012 |
Doot RK, Kurland BF, Kinahan PE, Mankoff DA. Design considerations for using PET as a response measure in single site and multicenter clinical trials. Academic Radiology. 19: 184-90. PMID 22104290 DOI: 10.1016/J.Acra.2011.10.008 |
0.347 |
|
| 2012 |
Linden HM, Kurland BF, Link J, Gadi VK, Specht JM, Gralow J, Schubert EK, Peterson L, Eary JF, Mankoff DA. Vorinostat to restore sensitivity to aromatase inhibitor therapy in metastatic breast cancer: A phase II clinical trial with ER imaging correlates. Journal of Clinical Oncology. 30: TPS3109-TPS3109. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps3109 |
0.411 |
|
| 2012 |
Austin M, Schmidt R, Parvathaneni U, Bauman JE, Hayes DN, Papagikos MA, Eaton KD, Liao JJ, Mendez E, Kurland BF, Xiaoyu S, Wallace SG, Martins R. Expression of p16, ERCC1, and EGFR amplification as predictors of responsiveness of locally advanced squamous cell carcinomas of head and neck (SCCHN) to cisplatin, radiotherapy, and erlotinib: A phase II randomized trial. Journal of Clinical Oncology. 30: 5515-5515. DOI: 10.1200/Jco.2012.30.15_Suppl.5515 |
0.324 |
|
| 2012 |
Martins R, Parvathaneni U, Sharma AK, Raez LE, Papagikos MA, Yunus F, Bauman JE, Eaton KD, Liao JJ, Mendez E, Futran N, Kurland BF, Wang DX, Xiaoyu S, Wallace SG, et al. Randomized phase II trial of cisplatin and radiotherapy with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology. 30: 5503-5503. DOI: 10.1200/Jco.2012.30.15_Suppl.5503 |
0.322 |
|
| 2012 |
Currin ER, Dunnwald LK, Doot RK, Schubert EK, Kurland BF, Mankoff DA, Specht JM. Quantitative measures of FDG PET after neoadjuvant chemotherapy to predict breast cancer patient survival. Journal of Clinical Oncology. 30: 1088-1088. DOI: 10.1200/Jco.2012.30.15_Suppl.1088 |
0.403 |
|
| 2012 |
Pidala J, Chai X, Kurland B, Arora M, Cutler C, Flowers ME, Inamoto Y, Jagasia M, Khera N, Palmer J, Vogelsang G, Lee SJ. Gastrointestinal and Hepatic Involvement in Chronic Gvhd: An Analysis From the Chronic Gvhd Consortium Blood. 120: 1940-1940. DOI: 10.1182/Blood.V120.21.1940.1940 |
0.301 |
|
| 2012 |
Linden H, Kurland B, Specht J, Vijayakrishn G, Gralow J, Peterson L, Schubert E, Link J, David M, Eary J, Krohn K. Abstract P6-04-03: Changes in breast tumor metabolism and estradiol binding as measured by FES PET in patients treated with the histone deacetylace inhibitor vorinostat and aromatase inhibitor therapy Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P6-04-03 |
0.413 |
|
| 2012 |
Krohn K, Linden H, Kurland B, Specht J, Gadi V, Peterson L, Schubert E, Link J, Mankoff D, Eary J. 456 FES PET is an Imaging Biomarker of Pharmacodynamic Response to Estrogen Receptor (ER) Modulating Therapies in Breast Cancer European Journal of Cancer. 48: 141. DOI: 10.1016/S0959-8049(12)72254-2 |
0.369 |
|
| 2011 |
Mankoff DA, Linden HM, Link J, Kurland BF, Schubert EK, Peterson L, Gadi VK, Specht JM, Shankar L, Eary JF. NCI-sponsored phase II study of [(18)f]fluoroestradiol (FES) as a marker of hormone sensitivity of metastatic breast cancer: Initial results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e11104. PMID 28023805 DOI: 10.1200/Jco.2011.29.15_Suppl.E11104 |
0.381 |
|
| 2011 |
Linden HM, Kurland BF, Livingston RB, Ellis GK, Gadi VK, Specht JM, Gralow J, Peterson L, Schubert EK, Xiaoyu S, Mankoff DA. Changes in FDG PET SUV and correlation with Ki-67 following 2 weeks of aromatase inhibitor therapy or trastuzumab in a pilot imaging study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e21077. PMID 28022217 DOI: 10.1200/Jco.2011.29.15_Suppl.E21077 |
0.37 |
|
| 2011 |
Peterson LM, Kurland BF, Link JM, Schubert EK, Stekhova S, Linden HM, Mankoff DA. Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. Nuclear Medicine and Biology. 38: 969-78. PMID 21982568 DOI: 10.1016/J.Nucmedbio.2011.03.002 |
0.379 |
|
| 2011 |
Kurland BF, Peterson LM, Lee JH, Linden HM, Schubert EK, Dunnwald LK, Link JM, Krohn KA, Mankoff DA. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 1541-9. PMID 21903739 DOI: 10.2967/Jnumed.111.091439 |
0.38 |
|
| 2011 |
Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM, Ellis GK, Lawton TJ, Livingston RB, Petra PH, Link JM, Krohn KA, Mankoff DA. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4799-805. PMID 21750198 DOI: 10.1158/1078-0432.Ccr-10-3321 |
0.364 |
|
| 2011 |
Dunnwald LK, Doot RK, Specht JM, Gralow JR, Ellis GK, Livingston RB, Linden HM, Gadi VK, Kurland BF, Schubert EK, Muzi M, Mankoff DA. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2400-9. PMID 21364034 DOI: 10.1158/1078-0432.Ccr-10-2649 |
0.384 |
|
| 2011 |
Demartini WB, Kurland BF, Gutierrez RL, Blackmore CC, Peacock S, Lehman CD. Probability of malignancy for lesions detected on breast MRI: a predictive model incorporating BI-RADS imaging features and patient characteristics. European Radiology. 21: 1609-17. PMID 21359910 DOI: 10.1007/S00330-011-2094-6 |
0.319 |
|
| 2011 |
Partridge SC, Rahbar H, Murthy R, Chai X, Kurland BF, Demartini WB, Lehman CD. Improved diagnostic accuracy of breast MRI through combined apparent diffusion coefficients and dynamic contrast-enhanced kinetics Magnetic Resonance in Medicine. 65: 1759-1767. PMID 21254208 DOI: 10.1002/Mrm.22762 |
0.32 |
|
| 2011 |
Specht J, Kurland B, Dunnwald L, Doot R, Eun J, Schubert E, Partridge S, Ellis G, Gadi V, Gralow J, Linden H, Rodler E, Mankoff D. P2-09-09: Dynamic FDG PET and DCE-MRI To Assess Tumor Metabolism and Blood Flow in Response to Neoadjuvant Sunitinib and Paclitaxel Followed by AC + G-CSF in Patients with Locally-Advanced (LABC) and/or Inflammatory Breast Cancer (IBC). Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P2-09-09 |
0.36 |
|
| 2011 |
Parsian S, Sun R, Kurland B, Rahbar H, Allison K, Specht J, DeMartini W, Lehman C, Partridge S. P2-08-03: Quantitative MRI for Noninvasive Prediction of Prognostic Markers in Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P2-08-03 |
0.358 |
|
| 2011 |
Rodler E, Specht J, Gadi V, Kurland B, Griffin M, Hammond J, Gralow J. P1-17-04: Phase I Study of PARP Inhibitor ABT-888 (Veliparib) in Combination with Cisplatin and Vinorelbine for Patients with Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-17-04 |
0.366 |
|
| 2011 |
Gadi V, Kurland B, Specht J, Rodler E, Korde L, Peterson L, Schubert E, Chai X, Mankoff D, Linden H. P1-06-25: Changes in FDG PET SUV Correlates with Ki-67 Following 2 Weeks of Aromatase Inhibitor Therapy in ER+ Early Stage Breast Cancer, a Pilot Imaging Study. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-06-25 |
0.399 |
|
| 2010 |
Partridge SC, Vanantwerp RK, Doot RK, Chai X, Kurland BF, Eby PR, Specht JM, Dunnwald LK, Schubert EK, Lehman CD, Mankoff DA. Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. Journal of Magnetic Resonance Imaging : Jmri. 32: 1124-31. PMID 21031518 DOI: 10.1002/Jmri.22362 |
0.386 |
|
| 2010 |
Specht JM, Kurland BF, Montgomery SK, Dunnwald LK, Doot RK, Gralow JR, Ellis GK, Linden HM, Livingston RB, Allison KH, Schubert EK, Mankoff DA. Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2803-10. PMID 20460489 DOI: 10.1158/1078-0432.Ccr-10-0026 |
0.379 |
|
| 2010 |
Partridge SC, Demartini WB, Kurland BF, Eby PR, White SW, Lehman CD. Differential diagnosis of mammographically and clinically occult breast lesions on diffusion-weighted MRI. Journal of Magnetic Resonance Imaging : Jmri. 31: 562-70. PMID 20187198 DOI: 10.1002/Jmri.22078 |
0.302 |
|
| 2010 |
Eby PR, Calhoun KE, Kurland BF, Demartini WB, Gutierrez RL, Peacock S, Anderson BO, Byrd DR, Mann GN, Lehman CD. Preoperative and intraoperative sonographic visibility of collagen-based breast biopsy marker clips. Academic Radiology. 17: 340-7. PMID 20042350 DOI: 10.1016/J.Acra.2009.10.017 |
0.302 |
|
| 2010 |
Montgomery SK, Kurland BF, Dunnwald LK, Doot RK, Livingston RB, Allison KH, Schubert EK, Mankoff DA, Specht JM. Use of PET to assess tumor metabolism and blood flow by tumor subtype in locally advanced breast cancer. Journal of Clinical Oncology. 28: 600-600. DOI: 10.1200/Jco.2010.28.15_Suppl.600 |
0.393 |
|
| 2009 |
Linden HM, Kurland BF, Livingston RB, Ellis GK, Gadi VK, Specht JM, Gralow JR, Mankoff DA, Peterson LM, Schubert EK. Early assessment of response to aromatase inhibitor (AI) therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 11075. PMID 27963199 DOI: 10.1200/Jco.2009.27.15_Suppl.11075 |
0.341 |
|
| 2009 |
Partridge SC, DeMartini WB, Kurland BF, Eby PR, White SW, Lehman CD. Quantitative diffusion-weighted imaging as an adjunct to conventional breast MRI for improved positive predictive value. Ajr. American Journal of Roentgenology. 193: 1716-22. PMID 19933670 DOI: 10.2214/Ajr.08.2139 |
0.31 |
|
| 2009 |
Gutierrez RL, DeMartini WB, Eby PR, Kurland BF, Peacock S, Lehman CD. BI-RADS lesion characteristics predict likelihood of malignancy in breast MRI for masses but not for nonmasslike enhancement. Ajr. American Journal of Roentgenology. 193: 994-1000. PMID 19770321 DOI: 10.2214/Ajr.08.1983 |
0.305 |
|
| 2009 |
Gutierrez RL, Demartini WB, Eby P, Kurland BF, Peacock S, Lehman CD. Clinical indication and patient age predict likelihood of malignancy in suspicious breast MRI lesions. Academic Radiology. 16: 1281-5. PMID 19733804 DOI: 10.1016/J.Acra.2009.04.012 |
0.33 |
|
| 2009 |
Deng Y, Kurland BF, Wang J, Bi J, Li W, Rao S, Lan P, Lin T, Lin E. High epidermal growth factor receptor expression in metastatic colorectal cancer lymph nodes may be more prognostic of poor survival than in primary tumor. American Journal of Clinical Oncology. 32: 245-52. PMID 19451802 DOI: 10.1097/Coc.0B013E3181891326 |
0.306 |
|
| 2009 |
Specht J, Partridge S, Dunnwald L, Doot R, Schubert E, Kurland B, Gralow J, Linden H, Gadi V, Ellis G, Mankoff D. DCE-MRI and dynamic FDG PET to monitor breast cancer response to neoadjuvant sunitinib in patients with locally-advanced breast cancer. Cancer Research. 69: 6006. DOI: 10.1158/0008-5472.Sabcs-6006 |
0.405 |
|
| 2009 |
Specht J, Kurland B, Dunnwald L, Doot R, Gralow J, Ellis G, Linden H, Livingston R, Schubert E, Mankoff D. Metabolism-perfusion mismatch as assessed by PET varies with breast cancer phenotype and predicts response to neoadjuvant chemotherapy. Cancer Research. 69: 6005. DOI: 10.1158/0008-5472.Sabcs-6005 |
0.412 |
|
| 2008 |
Deng Y, Kurland BF, Wang J, Bi J, Li W, Lan P, Lin T, Lin EH. High epidermal growth factor receptor expression in metastatic lymph nodes may be more prognostic than in primary tumor for colorectal cancer survival. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 15031. PMID 27949929 DOI: 10.1200/Jco.2008.26.15_Suppl.15031 |
0.301 |
|
| 2008 |
Eby PR, Partridge SC, White SW, Doot RK, Dunnwald LK, Schubert EK, Kurland BF, Lehman CD, Mankoff DA. Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer. Academic Radiology. 15: 1246-54. PMID 18790395 DOI: 10.1016/J.Acra.2008.03.019 |
0.362 |
|
| 2008 |
Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, Doot RK, Lawton TJ, Barlow WE, Kurland BF, Schubert EK, Mankoff DA. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4449-57. PMID 18626006 DOI: 10.1200/Jco.2007.15.4385 |
0.389 |
|
| 2007 |
Yao MS, Kurland BF, Smith AH, Schubert EK, Dunnwald LK, Byrd DR, Mankoff DA. Internal mammary nodal chain drainage is a prognostic indicator in axillary node-positive breast cancer. Annals of Surgical Oncology. 14: 2985-93. PMID 17564747 DOI: 10.1245/S10434-007-9473-X |
0.341 |
|
| 2007 |
Doot RK, Dunnwald LK, Schubert EK, Muzi M, Peterson LM, Kinahan PE, Kurland BF, Mankoff DA. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 920-5. PMID 17504870 DOI: 10.2967/Jnumed.106.037382 |
0.374 |
|
| 2007 |
Specht JM, Tam SL, Kurland BF, Gralow JR, Livingston RB, Linden HM, Ellis GK, Schubert EK, Dunnwald LK, Mankoff DA. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Research and Treatment. 105: 87-94. PMID 17268819 DOI: 10.1007/S10549-006-9435-1 |
0.39 |
|
| 2007 |
Partridge SC, Eby PR, Doot RK, White SW, Kurland BF, Schubert EK, Dunnwald LK, Lehman CD, Mankoff DA. Comparison of vascularity measures from PET and MRI for improved breast tumor characterization and therapeutic response evaluation Journal of Clinical Oncology. 25: 589-589. DOI: 10.1200/Jco.2007.25.18_Suppl.589 |
0.358 |
|
| 2007 |
Linden HM, Mankoff DA, Krohn KA, Link JM, Stekhova S, Livingston RB, Gralow JR, Ellis GK, Kurland B, Peterson L, Schubert EK. PET FES measures in vivo pharmacodynamics of endocrine therapy Journal of Clinical Oncology. 25: 14110-14110. DOI: 10.1200/Jco.2007.25.18_Suppl.14110 |
0.369 |
|
| 2005 |
Kurland BF, Heagerty PJ. Directly parameterized regression conditioning on being alive: analysis of longitudinal data truncated by deaths. Biostatistics (Oxford, England). 6: 241-58. PMID 15772103 DOI: 10.1093/Biostatistics/Kxi006 |
0.461 |
|
| 2004 |
Kurland BF, Heagerty PJ. Marginalized transition models for longitudinal binary data with ignorable and non-ignorable drop-out. Statistics in Medicine. 23: 2673-95. PMID 15316952 DOI: 10.1002/Sim.1850 |
0.452 |
|
| 2001 |
Heagerty PJ, Kurland BF. Misspecified maximum likelihood estimates and generalised linear mixed models Biometrika. 88: 973-985. DOI: 10.1093/Biomet/88.4.973 |
0.45 |
|
| Show low-probability matches. |